Under construction – not a live service
Sign in
Taking people in SpainNo phase

Checks how often amyloidosis is found in people having trauma surgery

Looks at how often amyloidosis occurs in patients undergoing trauma surgery.

Plain-language title generated from the registry record
Registry title: Prevalence of Amyloidosis in Trauma Patients

Key facts

Where
Sant Pere de Ribes, SpainSee the site

Where in Spain

  • Consorci Sanitari Alt Penedes i Garraf-Hospital Sant CamilSant Pere de Ribes, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Consorci Sanitari de l'Alt Penedès i Garraf
Trial code
NCT06527521
Record updated
27 October 2026
Original description
This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.Read full original descriptionShow less

Prevalence of Amyloidosis in Trauma Patients Using Red Flags Tool

This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.

Inclusion: Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness > 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP > 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause; Ability to cooperate in the necessary evaluations; Signed informed consent for inclusion in the study, either by the participant or their legal representative.

Exclusion: Participants previously diagnosed with amyloidosis cannot be included in the study.

ClinicalTrials.gov NCT06527521